Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for fatty liver (MASLD)
IRCT20250430065534N2Phase 2Completed
- Sponsor
- King Edward Medical University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by King Edward Medical University. Started Jun 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20250430065534N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250430065534N2.